Citigroup Inc Adverum Biotechnologies, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$1.5 - $2.33 $715,038 - $1.11 Million	476,692 New	476,692 $715,000
Q3 2022 Nov 10, 2022	SELL	$0.96 - $9.68 $1,176 - $11,867	-1,226 Reduced 50.79%	1,188 $1,000
Q2 2022 Aug 10, 2022	SELL	$0.81 - $1.34 $2,861 - $4,734	-3,533 Reduced 59.41%	2,414 $3,000
Q1 2022 May 12, 2022	SELL	$1.23 - $1.95 $23,988 - $38,030	-19,503 Reduced 76.63%	5,947 $8,000
Q4 2021 Feb 10, 2022	SELL	$1.74 - $2.4 $76,500 - $105,518	-43,966 Reduced 63.34%	25,450 $45,000
Q3 2021 Nov 10, 2021	BUY	$2.08 - $3.6 $144,385 - $249,897	69,416 New	69,416 $151,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.